Leucine raises $7 million in funding led by Ecolab
Leucine, a business-to-business startup that provides software to pharmaceutical firms in India and the US, announced that it had raised $7 million in a Series A fundraising round that was primarily driven by Ecolab. New York Stock Exchange listing The Minnesota-based business Ecolab offers services and solutions for water, hygiene, and infection control.
Pravega Ventures, Axilor Ventures, Techstars, and angel investors were among the additional investors. Leucine Co-Founder and CEO Vivek Gera stated that the firm will prioritise developing its go-to-market (GTM) motion, accelerating AI capabilities, and expanding the workforce during the following two to three quarters.
The software-as-a-service firm, which has operations in Bengaluru and Jersey City, assists its pharmaceutical manufacturing clients with batch planning through batch release, modernising established procedures and switching to a digital-first strategy in place of paper-based records. According to Gera, a batch execution method is the single most crucial document in the production of pharmaceuticals, and Leucine's digitization capacity shortens the cycle time for a batch record from 6 to 8 months to just 3-5 days.
Through an analytics dashboard that is powered by artificial intelligence, the platform also provides clients with information that they can act upon. Leucine10x, an AI-powered framework created to operate as a co-pilot in pharmaceutical production processes, has also been launched in beta, according to the business. "Our models are trained on a wealth of pharma data, which allows the platform to create custom workflows enriched with GxP compliance measures, enabling us to deliver unparalleled value at breakneck speed", Gera stated.
In 2019, Gera and Mustaq Singh Bijral established the business. Before founding his own business, Gera worked both independently and for Rio Tinto. Vivek and Mustaq have worked tirelessly to make pharmaceutical production safer. Leucine will be able to use the potential of LLMs (long language models) and related technologies as a result of the most recent fundraising round, according to Rohit Jain, Co-Founder and Partner at Pravega Ventures.
Pravega Ventures, Axilor Ventures, Techstars, and angel investors were among the additional investors. Leucine Co-Founder and CEO Vivek Gera stated that the firm will prioritise developing its go-to-market (GTM) motion, accelerating AI capabilities, and expanding the workforce during the following two to three quarters.
The software-as-a-service firm, which has operations in Bengaluru and Jersey City, assists its pharmaceutical manufacturing clients with batch planning through batch release, modernising established procedures and switching to a digital-first strategy in place of paper-based records. According to Gera, a batch execution method is the single most crucial document in the production of pharmaceuticals, and Leucine's digitization capacity shortens the cycle time for a batch record from 6 to 8 months to just 3-5 days.
Through an analytics dashboard that is powered by artificial intelligence, the platform also provides clients with information that they can act upon. Leucine10x, an AI-powered framework created to operate as a co-pilot in pharmaceutical production processes, has also been launched in beta, according to the business. "Our models are trained on a wealth of pharma data, which allows the platform to create custom workflows enriched with GxP compliance measures, enabling us to deliver unparalleled value at breakneck speed", Gera stated.
In 2019, Gera and Mustaq Singh Bijral established the business. Before founding his own business, Gera worked both independently and for Rio Tinto. Vivek and Mustaq have worked tirelessly to make pharmaceutical production safer. Leucine will be able to use the potential of LLMs (long language models) and related technologies as a result of the most recent fundraising round, according to Rohit Jain, Co-Founder and Partner at Pravega Ventures.
.jpg "Data Foundry: Pioneering Innovative AI Solutions for Safer Drug Discovery")
